Lamivudine Sandoz (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which competitively inhibits the reverse transcriptase enzyme of HIV and the DNA polymerase of hepatitis B virus. By incorporating into the viral DNA chain, it causes premature termination of DNA synthesis, blocking viral replication.

The specific dose of Lamivudine Sandoz is determined by the prescribing healthcare professional based on the patient’s condition, weight, renal function and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lamivudine in pregnancy and lactation are limited. The prescriber must weigh potential benefits against possible risks to the fetus or infant. If treatment is essential, lamivudine may be used under close medical supervision, but alternatives are considered when possible.

To order Lamivudine Sandoz, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and convenient oral dosing. Compared with some older NRTIs, it has lower mitochondrial toxicity and is often preferred in combination regimens, though drug‑specific choices depend on resistance patterns and patient tolerance.

Lamivudine tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Lamivudine Sandoz is administered orally, usually as a tablet taken with or without food. It is taken once daily or as directed by the prescriber, and patients should swallow the tablet whole with water and maintain a consistent dosing schedule.

Serious risks include lactic acidosis, severe hepatotoxicity, pancreatitis, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Hematologic abnormalities like anemia or neutropenia may also occur. Patients should be monitored regularly for these events, especially during the initial treatment period.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in pregnant or breastfeeding women unless the benefits clearly outweigh the risks.